Valeant pitches potential eye drug, research focus

Published



Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan.

Irvine, California-based Allergan Inc. has rejected several acquisition bids from Valeant, the latest amounting to about $53 billion. Its executives have said Valeant would slash research and development funding too much if it took over. They’ve also said the offers undervalue their company.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.